Proteoglycan degrading mutants for the treatment of CNS
View Patent ↗The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
1. A method of treating a tissue, the method comprising: administering a mutant proteoglycan degrading polypeptide composition to the tissue, wherein the polypeptide is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4.
2. The method of claim 1 , wherein the tissue is from the CNS.
3. The method of claim 1 , further comprising the act of identifying tissue from a contusive spinal cord injury.
4. The method of claim 1 , wherein the composition promotes neurite regeneration.
5. The method of claim 1 , wherein the composition further includes molecules which block the action of neurite growth inhibitors, molecules which promote neurite adhesion, diagnostic molecules or a combination of these.
6. The method of claim 1 , wherein the plasticity of the nervous system is improved.
7. The method of claim 1 , wherein the mutant proteoglycan degrading polypeptide degrades a proteoglycan in a tissue of the central nervous system.
8. The method of claim 7 , wherein the proteoglycan degradation promotes diffusion of molecules into the tissue.
9. The method of claim 1 , wherein the composition includes cells.
10. The method of claim 1 , wherein the composition comprises a pharmaceutically acceptable excipient.
11. A method of treating a tissue, the method comprising: administering a mutant proteoglycan degrading polypeptide composition to the tissue, wherein the proteoglycan degrading polypeptide is SEQ ID NO: 2.
12. The method of claim 11 , wherein the mutant proteoglycan degrading polypeptide degrades a proteoglycan in a tissue of the central nervous system.
13. The method of claim 12 , wherein the proteoglycan degradation promotes diffusion of molecules into the tissue.
14. The method of claim 11 , wherein the composition includes cells.
15. The method of claim 11 , wherein the composition comprises a pharmaceutically acceptable excipient.
16. The method of claim 11 , wherein the composition includes molecules that block the action of neurite growth inhibitors, molecules which promote neurite adhesion, diagnostic molecules or a combination of any thereof.
17. The method of claim 11 , wherein the composition promotes neurite regeneration.
18. The method of claim 11 , wherein the plasticity of the nervous system is improved.
19. A method of treating a tissue, the method comprising: administering a mutant proteoglycan degrading polypeptide composition to the tissue, wherein the proteoglycan degrading polypeptide is SEQ ID NO: 3.
20. The method of claim 19 , wherein the mutant proteoglycan degrading polypeptide degrades a proteoglycan in a tissue of the central nervous system.
21. The method of claim 20 , wherein the proteoglycan degradation promotes diffusion of molecules into the tissue.
22. The method of claim 19 , wherein the composition includes cells.
23. The method of claim 19 , wherein the composition comprises a pharmaceutically acceptable excipient.
24. The method of claim 19 , wherein the composition includes molecules that block the action of neurite growth inhibitors, molecules which promote neurite adhesion, diagnostic molecules or a combination of any thereof.
25. The method of claim 19 , wherein the composition promotes neurite regeneration.
26. The method of claim 19 , wherein the plasticity of the nervous system is improved.
27. A method of treating a tissue, the method comprising: administering a mutant proteoglycan degrading polypeptide composition to the tissue, wherein the proteoglycan degrading polypeptide is SEQ ID NO: 4.
28. The method of claim 27 , wherein the mutant proteoglycan degrading polypeptide degrades a proteoglycan in a tissue of the central nervous system.
29. The method of claim 28 , wherein the proteoglycan degradation promotes diffusion of molecules into the tissue.
30. The method of claim 27 , wherein the composition includes cells.
31. The method of claim 27 , wherein the composition comprises a pharmaceutically acceptable excipient.
32. The method of claim 27 , wherein the composition includes molecules that block the action of neurite growth inhibitors, molecules which promote neurite adhesion, diagnostic molecules or a combination of any thereof.
33. The method of claim 27 , wherein the composition promotes neurite regeneration.
34. The method of claim 27 , wherein the plasticity of the nervous system is improved.